Home › B-Cell Leukemia
Pag-aaral pangklinika para sa B-Cell Leukemia na nagre-recruit sa U.S.
17 pag-aaral para sa B-Cell Leukemia ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX7 pag-aaral
- Washington, DC5 pag-aaral
- Dallas, TX5 pag-aaral
- Columbus, OH4 pag-aaral
- Portland, OR4 pag-aaral
- Spokane, WA3 pag-aaral
- Pittsburgh, PA3 pag-aaral
- Louisville, KY3 pag-aaral
- Boston, MA3 pag-aaral
- San Diego, CA3 pag-aaral
- Edison, NJ3 pag-aaral
- Chicago, IL3 pag-aaral
- Denver, CO3 pag-aaral
- New York City, NY3 pag-aaral
- Charlotte, NC3 pag-aaral
- Philadelphia, PA3 pag-aaral
- Clifton, NJ3 pag-aaral
Ayos sa estado
- California7 pag-aaral
- Colorado3 pag-aaral
- Florida3 pag-aaral
- Illinois4 pag-aaral
- Kansas3 pag-aaral
- Kentucky3 pag-aaral
- Maryland5 pag-aaral
- Massachusetts3 pag-aaral
- Minnesota3 pag-aaral
- New Jersey4 pag-aaral
- New York4 pag-aaral
- North Carolina5 pag-aaral
- Ohio7 pag-aaral
- Oregon4 pag-aaral
- Pennsylvania5 pag-aaral
- Texas12 pag-aaral
- Washington5 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 110 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT00923507Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Nagre-recruitPhase 4
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06651970Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT04728893Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Nagre-recruitPhase 1
Hanggang edad 75 · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06345027Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Nagre-recruitPhase 3
Edad 18 hanggang 18 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07509151A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06564038Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
Nagre-recruitPhase 1
12 Months – 25 Years · Lahat ng kasarian · Na-update Set 4, 2026 · NCT05010564Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Nagre-recruitPhase 2
Edad 7 hanggang 25 · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT05082519A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT05254743ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT07342478A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT06542250A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT06708897CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Nagre-recruitPhase 1/2
Edad 3 hanggang 39 · Lahat ng kasarian · Na-update Hul 30, 2026 · NCT05442515The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Nagre-recruitPhase 1/2
Edad 12 hanggang 95 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT04329728A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Nagre-recruitPhase 2
Edad 18 hanggang 66 · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06859424A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Nagre-recruitObservasyonal na pag-aaral
Edad 1 hanggang 23 · Lahat ng kasarian · Na-update Peb 25, 2026 · NCT07422337Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Ene 22, 2026 · NCT06357754Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.